A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 21, 2021

Primary Completion Date

July 1, 2021

Study Completion Date

October 19, 2021

Conditions
Acute Ischemic Stroke
Interventions
DRUG

LT3001 drug product

Multiple doses of LT3001 drug product administered by intravenous infusion

DRUG

Placebo

Multiple doses of Placebo administered by intravenous infusion

DRUG

Aspirin

Loading and maintenance doses of Aspirin administered by oral

DRUG

Clopidogrel

Loading and maintenance doses of Clopidogrel administered by oral

DRUG

Apixaban

Multiple doses of Apixaban administered by oral

DRUG

Dabigatran

Multiple doses of Dabigatran administered by oral

Trial Locations (1)

90630

RECRUITING

Lumosa Phase 1 Unit, Cypress

Sponsors
All Listed Sponsors
lead

Lumosa Therapeutics Co., Ltd.

INDUSTRY